Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€4.21

€4.21

-0.940%
-0.04
-0.940%
-
 
15.12.25 / Frankfurt WKN: A3C7A5 / Name: Maat Pharma S.a. / Stock / ? /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

Maat Pharma S.a. Stock

The price for the Maat Pharma S.a. stock decreased slightly today. Compared to yesterday there is a change of -€0.040 (-0.940%).
Criterium "Worthwhile Investment for the next years" is seen as the biggest plus for Maat Pharma S.a. stock. Negative votes have not been in the majority for any criteria for this stock

Pros and Cons of Maat Pharma S.a. in the next few years

Pros
?
M***** P*******
?
C******** o* t** e**********
?
B****
Cons
?
G***** c******* t* c**********
?
S********** s********
?
W********* I********* f** t** n*** y****
Tell us your opinion to access the 'Wisdom of the Crowds'

News

MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe
MaaT Pharma Announces Exclusive Commercialization Partnership With Clinigen for Xervyteg® in acute Graft-versus Host Disease in Europe


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to

MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025
MaaT Pharma Provides a Business Update and Highlights Key Milestones Expected in 2025


Regulatory News:



MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to